Compound ID | 345
RWJ-442831
Class: Beta-lactam
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Combined with other compounds: | Could be combined with aztreonam, fosfomycin, gentamicin or levofloxacin for empiric therapy |
| Institute where first reported: | Microcide Pharmaceuticals; Essential Therapeutics, USA (Ceased); Johnson & Johnson Pharmaceutical |
| Year first mentioned: | 2000 |
| Development status: | Experimental |
| Reason dropped: | The collaboration between Johnson and Johnson Pharma and Essential Therapeutics which seems to have stopped with the closure of Essential Therapeutics |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.